National Immunobiological Company (or Nacimbio) pharmaceutical holding was established by Rostec State Corporation in 2013 to promote the development of enterprises of the Russian immunobiological industry and ensure the national independence of Russia in the production of biological medicinal products. It owns leading pharmaceutical enterprises NPO Microgen and FORT (10 assets in total). Nacimbio specializes in R&D, full cycle production and sales of vaccines, toxoids, blood products, allergens and allergoids, sera, bacteriophages, etc. The holding’s product portfolio includes more than 220 types of medicines.